Farhang Yazdchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Farhang Yazdchi has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Sameer A. Hirji
Brigham and Women’s Hospital, Harvard Medical School
6 shared publications - Tsuyoshi Kaneko
Division of Cardiothoracic Surgery, Washington University School of Medicine, St Louis, Missouri, USA
6 shared publications Edward Percy
Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
3 shared publications- Morgan Harloff
Division of Cardiac Surgery, Department of Surgery, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
3 shared publications - Prem S. Shekar
Rochester General Hospital, Rochester, NY, USA
3 shared publications - Siobhan McGurk
Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
3 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2025 (1)
Hypothermic Low Flow Fibrillation for Unclampable Aorta in Coronary Artery Bypass Grafting: Alternative to Off‐Pump CABG
Background: Severe calcific disease of the ascending aorta may prohibit cross‐clamping during coronary artery bypass grafting (CABG) due to unacceptable morbidity and mortality associated with atheroembolic complications. Clampless hypothermic noncardioplegic low flow fibrillation (HLFF) may minimize neurologic complications while allowing for complete revascularization. Methods: From 2002 to 2019, 142 patients with unclampable aorta (UCA) underwent isolated CABG using clampless HLFF. Short‐term and long‐term outcomes were compared with an isolated conventional on‐pump CABG cohort ( n = 268) risk‐matched (RM) for type of CABG, STS score, age, and sex. Results: UCA and RM cohort patients were comparable in terms of age (73.7 ± 7.8 vs. 72.7 ± 8.7, p = 0.281), sex (34.4% vs. 32.5% female, p = 1.000), STS score (4.01 ± 3.43 vs. 3.80 ± 3.33, p = 0.539), and number of diseased vessels ( p = 0.323). 90% of patients underwent central cannulation; UCA group patients received a comparable number of arterial ( p = 0.432) or venous grafts ( p = 0.493). Incidence of stroke was 6.3% in the UCA cohort and 2.6% in the RM cohort ( p = 0.059). Need for reoperation, postoperative transfusions, incidence of atrial fibrillation, and renal impairment was similar (all p > 0.050). UCA patients spent a longer time on the ventilator, in the ICU, and in the hospital (all p = 0.001). Operative mortality was not different between UCA and RM groups (3.5% vs. 4.5%, p = 0.797) as was all‐cause mortality over long‐term follow‐up ( p = 0.093). Conclusions: While a higher incidence of stroke was observed, without reaching statistical significance, hypothermic fibrillatory arrest remains a valuable and safe tool for coronary revascularization in UCA patients, offering comparable short‐term and long‐term survival outcomes allowing for complete revascularization.
- 1 January 2025
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2025 (1)
Open AccessHypothermic Low Flow Fibrillation for Unclampable Aorta in Coronary Artery Bypass Grafting: Alternative to Off‐Pump CABG
Background: Severe calcific disease of the ascending aorta may prohibit cross‐clamping during coronary artery bypass grafting (CABG) due to unacceptable morbidity and mortality associated with atheroembolic complications. Clampless hypothermic noncardioplegic low flow fibrillation (HLFF) may minimize neurologic complications while allowing for complete revascularization. Methods: From 2002 to 2019, 142 patients with unclampable aorta (UCA) underwent isolated CABG using clampless HLFF. Short‐term and long‐term outcomes were compared with an isolated conventional on‐pump CABG cohort ( n = 268) risk‐matched (RM) for type of CABG, STS score, age, and sex. Results: UCA and RM cohort patients were comparable in terms of age (73.7 ± 7.8 vs. 72.7 ± 8.7, p = 0.281), sex (34.4% vs. 32.5% female, p = 1.000), STS score (4.01 ± 3.43 vs. 3.80 ± 3.33, p = 0.539), and number of diseased vessels ( p = 0.323). 90% of patients underwent central cannulation; UCA group patients received a comparable number of arterial ( p = 0.432) or venous grafts ( p = 0.493). Incidence of stroke was 6.3% in the UCA cohort and 2.6% in the RM cohort ( p = 0.059). Need for reoperation, postoperative transfusions, incidence of atrial fibrillation, and renal impairment was similar (all p > 0.050). UCA patients spent a longer time on the ventilator, in the ICU, and in the hospital (all p = 0.001). Operative mortality was not different between UCA and RM groups (3.5% vs. 4.5%, p = 0.797) as was all‐cause mortality over long‐term follow‐up ( p = 0.093). Conclusions: While a higher incidence of stroke was observed, without reaching statistical significance, hypothermic fibrillatory arrest remains a valuable and safe tool for coronary revascularization in UCA patients, offering comparable short‐term and long‐term survival outcomes allowing for complete revascularization.
- Open Access
- 1 September 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 15 (9) , e011756
Association Between Peripheral Versus Central Access for Alternative Access Transcatheter Aortic Valve Replacement and Mortality and Stroke: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry
Background: In some patients, the alternative access route for transcatheter aortic valve replacement (TAVR) is utilized because the conventional transfemoral approach is not felt to be either feasible or optimal. However, accurate prognostication of patient risks is not well established. This study examines the associations between peripheral (transsubclavian/transaxillary, and transcarotid) versus central access (transapical and transaortic) in alternative access TAVR and 30-day and 1-year end points of mortality and stroke for all valve platforms. Methods: Using data from The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry with linkage to Medicare claims, patients who underwent alternative access TAVR from June 1, 2015 to June 30, 2018 were identified. Adjusted and unadjusted Cox proportional hazards modeling were performed to determine the association between alternate access TAVR site and 30-day and 1-year end points of mortality and stroke. Results: Of 7187 alternative access TAVR patients, 3725 (52%) had peripheral access and 3462 (48%) had central access. All-cause mortality was significantly lower in peripheral access versus central access group at in-hospital and 1 year (2.9% versus 6.3% and 20.3% versus 26.6%, respectively), but stroke rates were higher (5.0% versus 2.8% and 7.3% versus 5.5%, respectively; all P P <0.05). Conclusions: In this real-world, contemporary, nationally representative benchmarking study of alternate access TAVR sites, peripheral access was associated with favorable mortality and morbidity outcomes compared with central access, at the expense of higher stroke. These findings may allow for accurate prognostication of risk for patient counseling and decision-making for the heart team with regard to alternative access TAVR.
- 1 September 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 15 (9) , e011756
Open AccessAssociation Between Peripheral Versus Central Access for Alternative Access Transcatheter Aortic Valve Replacement and Mortality and Stroke: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry
Background: In some patients, the alternative access route for transcatheter aortic valve replacement (TAVR) is utilized because the conventional transfemoral approach is not felt to be either feasible or optimal. However, accurate prognostication of patient risks is not well established. This study examines the associations between peripheral (transsubclavian/transaxillary, and transcarotid) versus central access (transapical and transaortic) in alternative access TAVR and 30-day and 1-year end points of mortality and stroke for all valve platforms. Methods: Using data from The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry with linkage to Medicare claims, patients who underwent alternative access TAVR from June 1, 2015 to June 30, 2018 were identified. Adjusted and unadjusted Cox proportional hazards modeling were performed to determine the association between alternate access TAVR site and 30-day and 1-year end points of mortality and stroke. Results: Of 7187 alternative access TAVR patients, 3725 (52%) had peripheral access and 3462 (48%) had central access. All-cause mortality was significantly lower in peripheral access versus central access group at in-hospital and 1 year (2.9% versus 6.3% and 20.3% versus 26.6%, respectively), but stroke rates were higher (5.0% versus 2.8% and 7.3% versus 5.5%, respectively; all P P <0.05). Conclusions: In this real-world, contemporary, nationally representative benchmarking study of alternate access TAVR sites, peripheral access was associated with favorable mortality and morbidity outcomes compared with central access, at the expense of higher stroke. These findings may allow for accurate prognostication of risk for patient counseling and decision-making for the heart team with regard to alternative access TAVR.
- 1 January 2022
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 34 (2) , 585-594
Enhanced Recovery After Cardiac Surgery: A Propensity-Matched Analysis
- 1 January 2022
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 34 (2) , 585-594
Enhanced Recovery After Cardiac Surgery: A Propensity-Matched Analysis
- Open Access
- 1 August 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (29) , 2747-2755
Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes
We sought to perform a head-to-head comparison of contemporary 30-day outcomes and readmissions between valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) patients and a matched cohort of high-risk reoperative surgical aortic valve replacement (re-SAVR) patients using a large, multicentre, national database. We utilized the nationally weighted 2012–16 National Readmission Database claims to identify all US adult patients with degenerated bioprosthetic aortic valves who underwent either VIV-TAVR (n = 3443) or isolated re-SAVR (n = 3372). Thirty-day outcomes were compared using multivariate analysis and propensity score matching (1:1). Unadjusted, VIV-TAVR patients had significantly lower 30-day mortality (2.7% vs. 5.0%), 30-day morbidity (66.4% vs. 79%), and rates of major bleeding (35.8% vs. 50%). On multivariable analysis, re-SAVR was a significant risk factor for both 30-day mortality [adjusted odds ratio (aOR) of VIV-SAVR (vs. re-SAVR) 0.48, 95% confidence interval (CI) 0.28–0.81] and 30-day morbidity [aOR for VIV-TAVR (vs. re-SAVR) 0.54, 95% CI 0.43–0.68]. After matching (n = 2181 matched pairs), VIV-TAVR was associated with lower odds of 30-day mortality (OR 0.41, 95% CI 0.23–0.74), 30-day morbidity (OR 0.53, 95% CI 0.43–0.72), and major bleeding (OR 0.66, 95% CI 0.51–0.85). Valve-in-valve TAVR was also associated with shorter length of stay (median savings of 2 days, 95% CI 1.3–2.7) and higher odds of routine home discharges (OR 2.11, 95% CI 1.61–2.78) compared to re-SAVR. In this large, nationwide study of matched high-risk patients with degenerated bioprosthetic aortic valves, VIV-TAVR appears to confer an advantage over re-SAVR in terms of 30-day mortality, morbidity, and bleeding complications. Further studies are warranted to benchmark in low- and intermediate-risk patients and to adequately assess longer-term efficacy.
- 1 August 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (29) , 2747-2755
Open AccessComparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes
We sought to perform a head-to-head comparison of contemporary 30-day outcomes and readmissions between valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) patients and a matched cohort of high-risk reoperative surgical aortic valve replacement (re-SAVR) patients using a large, multicentre, national database. We utilized the nationally weighted 2012–16 National Readmission Database claims to identify all US adult patients with degenerated bioprosthetic aortic valves who underwent either VIV-TAVR (n = 3443) or isolated re-SAVR (n = 3372). Thirty-day outcomes were compared using multivariate analysis and propensity score matching (1:1). Unadjusted, VIV-TAVR patients had significantly lower 30-day mortality (2.7% vs. 5.0%), 30-day morbidity (66.4% vs. 79%), and rates of major bleeding (35.8% vs. 50%). On multivariable analysis, re-SAVR was a significant risk factor for both 30-day mortality [adjusted odds ratio (aOR) of VIV-SAVR (vs. re-SAVR) 0.48, 95% confidence interval (CI) 0.28–0.81] and 30-day morbidity [aOR for VIV-TAVR (vs. re-SAVR) 0.54, 95% CI 0.43–0.68]. After matching (n = 2181 matched pairs), VIV-TAVR was associated with lower odds of 30-day mortality (OR 0.41, 95% CI 0.23–0.74), 30-day morbidity (OR 0.53, 95% CI 0.43–0.72), and major bleeding (OR 0.66, 95% CI 0.51–0.85). Valve-in-valve TAVR was also associated with shorter length of stay (median savings of 2 days, 95% CI 1.3–2.7) and higher odds of routine home discharges (OR 2.11, 95% CI 1.61–2.78) compared to re-SAVR. In this large, nationwide study of matched high-risk patients with degenerated bioprosthetic aortic valves, VIV-TAVR appears to confer an advantage over re-SAVR in terms of 30-day mortality, morbidity, and bleeding complications. Further studies are warranted to benchmark in low- and intermediate-risk patients and to adequately assess longer-term efficacy.